AUTHOR=Talaat Iman M. , Yakout Nada M. , Soliman Ahmed S.A. , Venkatachalam Thenmozhi , Vinod Arya , Eldohaji Leen , Nair Vidhya , Hareedy Amal , Kandil Alaa , Abdel-Rahman Wael M. , Hamoudi Rifat , Saber-Ayad Maha TITLE=Evaluation of Galanin Expression in Colorectal Cancer: An Immunohistochemical and Transcriptomic Study JOURNAL=Frontiers in Oncology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.877147 DOI=10.3389/fonc.2022.877147 ISSN=2234-943X ABSTRACT=
Colorectal cancer (CRC) represents around 10% of all cancers, with an increasing incidence in the younger age group. The gut is considered a unique organ with its distinctive neuronal supply. The neuropeptide, human galanin, is widely distributed in the colon and expressed in many cancers, including the CRC. The current study aimed to explore the role of galanin at different stages of CRC. Eighty-one CRC cases (TNM stages I – IV) were recruited, and formalin-fixed paraffin-embedded samples were analyzed for the expression of galanin and galanin receptor 1 (GALR1) by immunohistochemistry (IHC). Galanin intensity was significantly lower in stage IV (n= 6) in comparison to other stages (p= 0.037 using the Mann-Whitney U test). Whole transcriptomics analysis using NGS was performed for selected samples based on the galanin expression by IHC [early (n=5) with high galanin expression and late (n=6) with low galanin expression]. Five differentially regulated pathways (using Absolute GSEA) were identified as drivers for tumor progression and associated with higher galanin expression, namely, cell cycle, cell division, autophagy, transcriptional regulation of TP53, and immune system process. The top shared genes among the upregulated pathways are